Navigation Links
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
Date:6/4/2008

Private offering provides new funding as Arno Therapeutics, Inc. becomes a

publicly reporting company.

FAIRFIELD, N.J., June 4 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for the treatment of cancer, announced the successful completion of its merger with Laurier International, Inc., a publicly traded company currently traded under the ticker symbol "LRRI.OB". Arno will continue to trade under the symbol LRRI.OB until such time as it receives a new symbol.

As previously announced on March 5, 2008, Arno, Laurier and Laurier Acquisition, Inc., a wholly-owned subsidiary of Laurier, entered into a merger agreement pursuant to which Laurier Acquisition would merge into Arno, with Arno becoming the wholly-owned subsidiary of Laurier. The merger was completed on June 3, 2008. Immediately thereafter, Arno merged with and into Laurier, and Laurier changed its name to Arno Therapeutics, Inc. In addition, upon the completion of the merger, the officers and directors of the former Arno Therapeutics became the officers and directors of the resulting company.

Prior to the merger, Arno completed an $18 million private financing through the sale of shares of common stock to an investor group comprised of select institutional and qualified investors. Riverbank Capital Securities, Inc., a FINRA member broker dealer, acted as placement agent in connection with the financing.

"We are extremely excited about the successful financing and merger, which leaves us in a strong position to advance our pipeline as rapidly as possible," said Scott Fields, M.D., President and Chief Medical Officer of Arno. "We look forward to moving into Phase II clinical studies with our lead product, AR-67, and to completing IND enabling pre-clinical work for AR-12 and AR-42."

The proceeds from the financing will be used primarily to fund further development of Arno's oncology pipe
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
10. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
11. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... TORONTO , June 17, 2013  Generex ... it entered into a securities purchase agreement with certain ... agreed to purchase in a private placement an aggregate ... Series E 9% Convertible Preferred Stock ("convertible preferred stock") ... 100% of the shares of its common stock issuable ...
(Date:6/17/2013)... -- Franciscan St. Francis Health Cancer Center today ... Indiana to use a new drug to treat ... Xofigo ®, a radiopharmaceutical used in patients with late-stage, ... was approved for use by the U.S. Food and Drug ... it may become castration-resistant, which has become resistant to medical ...
(Date:6/17/2013)... OSAKA, Japan , June 17, 2013 ... Takeda Pharmaceuticals U.S.A. , Inc. today ... KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and ... the United States (U.S.). These ... Administration (FDA) for the treatment of type 2 diabetes ...
Breaking Medicine Technology:Generex Announces $1,225,000 Capital Investment 2Generex Announces $1,225,000 Capital Investment 3Generex Announces $1,225,000 Capital Investment 4Generex Announces $1,225,000 Capital Investment 5New drug proving effective in attacking advanced prostate cancer 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 3Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 4Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 5Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 6Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 7Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 8Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 9
(Date:6/17/2013)... According to a June 11, 2013 ABC News article, ... information surfaces about the negative effects of sun on ... one’s skin care routine, as the sun's rays ... , “I agree with the article's suggestions for the best ... of Epione Beverly Hills. “Apply a minimum of SPF 30, ...
(Date:6/17/2013)... Harvard Stem Cell Institute (HSCI) researchers have identified in ... to regulate embryonic stem cell self-renewal, beginning a creative ... , The gene, SALL4, gives stem cells their ability ... mature cells. Typically, cells only express SALL4 during embryonic ... cases of acute myeloid leukemia and 10 to 30 ...
(Date:6/17/2013)... childhood obesity, researchers at the Johns Hopkins Bloomberg ... are important. A systematic review of childhood obesity ... incorporate schools and focus on both diet and ... in children. The results of the study appear ... "In measuring the effectiveness of community-based programs that ...
(Date:6/17/2013)... pyrvinium pamoate inhibits aggressive forms of prostate cancer that ... conducted in an animal model. The results will be ... in San Francisco. , "Our novel prostate cancer drug ... lead author Jeremy Jones, PhD, assistant professor of molecular ... Duarte, CA. "Thus, it has the potential to treat ...
(Date:6/17/2013)... Reliable services of Link to Pay have been offered to ... can fix payment processing. , Schools and colleges have a ... fees from students and processing them may be a herculean ... cases, colleges and universities are looking for some smart solutions ... efficiently without any complications. , At the same time, parents ...
Breaking Medicine News(10 mins):Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:A new target for cancer drug development 2Health News:Community-based programs may help prevent childhood obesity 2Health News:New medication treats drug-resistant prostate cancer in the laboratory 2Health News:PayCanada Offers Link to Pay Services to its Customers 2
... Legislature,took an important step to help combat the rise ... according to the Michigan Dermatological Society,(MDS). , ... Frank Accavitti (D-Eastpointe), regulates,tanning salons by specifically requiring onsite ... tanning facilities listing potential health,consequences, and a signed informed ...
... company, explains the repercussions and risks of waiting to file for SSDI. ... ... the mistake of waiting too long to apply for Social Security disability ... people in the Social Security Disability Insurance (SSDI) process each ...
... With everyone mindful of,budgets and spending this holiday ... routine perfume or socks and to give gifts that ... too. Finding special gifts for loved ones with,asthma ... and allergy friendly(TM),Certification Program is helping holiday shoppers all ...
... Dec. 11 The following is a statement from Peter ... United States: , , The ... decline in underage drinking. The study,s authors point out that ... of alcohol by those under the legal drinking age. The ...
... Million Patient Pavilion , , CAMDEN, ... filled lobby as visitors gather in the coffee shop sipping lattes ... is the new patient Pavilion at Cooper University Hospital. Cooper celebrated ... a spectacular "Grand Lighting" of the Pavilion. , ...
... 11 Bioenergy Life Science -- The Ribose,Company ... Solutions, LLC, to market,Bioenergy D-Ribose(TM) in the Eastern ... to stimulate the synthesis of adenosine,triphosphate (ATP) -- ... "Collaborating with Xsto Solutions will ...
Cached Medicine News:Health News:Dermatologists Applaud Passage of Tanning Salon Regulation 2Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 2Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 3Health News:Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits 4Health News:Spend Wisely This Holiday, Find Gifts That Are Good Fun and Good For You 2Health News:Spend Wisely This Holiday, Find Gifts That Are Good Fun and Good For You 3Health News:Cooper Opens Doors to New Era in Healthcare 2Health News:Cooper Opens Doors to New Era in Healthcare 3Health News:Bioenergy Life Science Retains Xsto Solutions to Market D-Ribose 2
The Solar Radius Chair is a multi-functional and cost effective working environment. It can be used for simple and advanced urodynamic studies as well as for routine gynecology investigations....
... The Sonesta 6202 is the ... with our most popular accessories, ... for a myriad of exam ... (yet quiet) motors allow fast ...
... Model BR2 Bilirubin STAT-Analyzer® provides a rapid, ... in neonates. And because it's so compact ... for virtually any laboratory. The Model BR2 ... the only instrument that measures total and ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: